FERAHEME
Total Payments
$5.6M
Transactions
11,555
Doctors
4,930
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $195,889 | 56 | 2 |
| 2023 | $364,589 | 65 | 5 |
| 2022 | $366,885 | 912 | 711 |
| 2021 | $486,616 | 2,307 | 1,534 |
| 2020 | $791,203 | 770 | 613 |
| 2019 | $1.6M | 2,678 | 1,558 |
| 2018 | $541,132 | 2,072 | 1,267 |
| 2017 | $1.2M | 2,695 | 1,369 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.1M | 678 | 56.7% |
| Grant | $710,109 | 21 | 12.8% |
| Consulting Fee | $667,988 | 188 | 12.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $449,730 | 158 | 8.1% |
| Honoraria | $138,700 | 48 | 2.5% |
| Travel and Lodging | $121,259 | 503 | 2.2% |
| Education | $116,992 | 6,548 | 2.1% |
| Food and Beverage | $101,525 | 3,381 | 1.8% |
| Space rental or facility fees (teaching hospital only) | $51,600 | 29 | 0.9% |
| Royalty or License | $50,000 | 1 | 0.9% |
Payments by Type
Research
$3.1M
678 transactions
General
$2.4M
10,877 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| INTRAVENOUS INFUSIONS OF FERUMOXYTOL COMPARED TO ORAL FERROUS SULFATE FOR THE TREATMENT OF ANEMIA IN PREGNANCY A RANDOMIZED CONTROLLED TRIAL | AMAG Pharmaceuticals, Inc. | $795,276 | 0 |
| A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, SAFETY STUDY OF FERUMOXYTOL COMPARED TO FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IDA FIRM | AMAG Pharmaceuticals, Inc. | $680,712 | 3 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA (IDA) IN PEDIATRIC SUBJECTS | AMAG Pharmaceuticals, Inc. | $276,141 | 0 |
| Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain | AMAG Pharmaceuticals, Inc. | $249,819 | 0 |
| Early Antenatal Support for Iron Deficiency Anemia: A Randomized Controlled Trial of Early Initiation of Intravenous Versus Oral Iron Therapy for Treatment of Iron Deficiency Anemia in Pregnancy | AMAG Pharmaceuticals, Inc. | $192,457 | 0 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA (IDA) IN PEDIATRIC SUBJECTS WITH CHRONIC KIDNEY DISEASE | AMAG Pharmaceuticals, Inc. | $166,082 | 2 |
| Superiority and clinical value high res steady state CBV mapping using Ferumoxytol | AMAG Pharmaceuticals, Inc. | $161,710 | 0 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY COMPARED TO IRON SUCROSE, EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IDA IN PEDIATRIC SUBJECTS WITH CHRONIC KIDNEY DISEASE | AMAG Pharmaceuticals, Inc. | $98,170 | 0 |
| Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients with Glioblastoma | AMAG Pharmaceuticals, Inc. | $75,190 | 0 |
| Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain and Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain | AMAG Pharmaceuticals, Inc. | $69,593 | 0 |
| Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain and Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain: confirmatory study | AMAG Pharmaceuticals, Inc. | $58,008 | 0 |
| HIGH RESOLUTION MRI OF INFLAMMATION IN THE INTERCRANIAL ARTERIAL VESSELL WALL | AMAG Pharmaceuticals, Inc. | $47,706 | 0 |
| Intravenous infusions of ferumoxytol compared to oral ferrous sulfate for the treatment of anemia in pregnancy A randomized controlled trial | AMAG Pharmaceuticals, Inc. | $44,009 | 0 |
| Ferumoxytol-enhanced magnetic resonance angiography has greater accuracy than cardiac PET/CT to identify clinically significant epicardial coronary artery stenosis | AMAG Pharmaceuticals, Inc. | $34,613 | 0 |
| Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain: confirmatory study | AMAG Pharmaceuticals, Inc. | $28,350 | 0 |
| Efficacy and Safety of Low-Dose Ferumoxytol for Vascular Suppression in Magnetic Resonance Neurography (MRN) | AMAG Pharmaceuticals, Inc. | $26,518 | 0 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IDA IN PEDIATRIC SUBJECTS | AMAG Pharmaceuticals, Inc. | $23,158 | 0 |
| Ferumoxytol-Enhanced Magnetic Resonance Angiography for the Evaluation of Pulmonary Embolism in Patients with Chronic Kidney Disease | AMAG Pharmaceuticals, Inc. | $20,764 | 0 |
| PILOT STUDY RANDOMIZED PLACEBO CONTROLLED TRIAL OF IV VERSUS ORAL IRON OF RESTLESS LEG SYNDROME WITH IRON DEFICINCY ANEMIA | AMAG Pharmaceuticals, Inc. | $20,458 | 0 |
| Ferumoxytol enhanced cardiac stress MRI in patients with kidney disease | AMAG Pharmaceuticals, Inc. | $18,513 | 0 |
Top Doctors Receiving Payments for FERAHEME — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| John Barton | — | Lexington, KY | $12,159 | 9 |
| , MD | Emergency Medicine | Salt Lake City, UT | $11,821 | 9 |
| , M.D | Hematology & Oncology | Flint, MI | $11,746 | 21 |
| , MD | Obstetrics & Gynecology | Columbus, OH | $11,556 | 9 |
| , M.D | Obstetrics & Gynecology | Houston, TX | $11,439 | 9 |
| , MD | Anesthesiology | Englewood, NJ | $11,329 | 11 |
| , M.D | Hematology | New York, NY | $11,257 | 9 |
| , M.D | Medical Oncology | La Jolla, CA | $10,753 | 10 |
| , M.D | Hematology & Oncology | Munster, IN | $10,707 | 14 |
| , MD | Gastroenterology | New York, NY | $8,586 | 7 |
| , M.B., B.S | Gastroenterology | La Jolla, CA | $8,540 | 5 |
| , M.D | Medical Oncology | San Antonio, TX | $8,380 | 7 |
| , MD | Surgery | Cleveland, OH | $8,247 | 11 |
| , M.D., PH. D | Medical Oncology | Miami, FL | $8,216 | 10 |
| , M.D | Hematology & Oncology | Cleveland, OH | $8,209 | 18 |
| , MD | Gastroenterology | Chapel Hill, NC | $8,208 | 7 |
| , M.D | Hematology & Oncology | Baltimore, MD | $8,048 | 19 |
| , MD | Internal Medicine | Stanford, CA | $7,856 | 12 |
| , MD | Gastroenterology | Cincinnati, OH | $7,714 | 11 |
| , MD | Maternal & Fetal Medicine | Portland, OR | $7,576 | 7 |
| , MD | Medical Oncology | Washington, DC | $7,191 | 13 |
| , M.D | Obstetrics & Gynecology | Chicago, IL | $6,969 | 7 |
| , MD | Gastroenterology | Morristown, NJ | $6,940 | 6 |
| , M.D, | Obstetrics & Gynecology | Berkeley, CA | $6,799 | 6 |
| , M.D | Gastroenterology | Boston, MA | $6,600 | 7 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.6M
- Total Doctors 4,930
- Transactions 11,555
About FERAHEME
FERAHEME is a drug associated with $5.6M in payments to 4,930 healthcare providers, recorded across 11,555 transactions in the CMS Open Payments database. The primary manufacturer is AMAG Pharmaceuticals, Inc..
Payment data is available from 2017 to 2024. In 2024, $195,889 was paid across 56 transactions to 2 doctors.
The most common payment nature for FERAHEME is "Unspecified" ($3.1M, 56.7% of total).
FERAHEME is associated with 20 research studies, including "INTRAVENOUS INFUSIONS OF FERUMOXYTOL COMPARED TO ORAL FERROUS SULFATE FOR THE TREATMENT OF ANEMIA IN PREGNANCY A RANDOMIZED CONTROLLED TRIAL" ($795,276).